Sparsentan has not yet been approved for marketing in Chinese Mainland. Patients need to obtain the drug through overseas channels, but they need to pay attention to drug quality and legal risks.

1. Domestic listing status

(1) Approval status: As of September 2025, the China National Medical Products Administration has not yet approved the marketing and sale of Sipasentan.

(2) Medical insurance coverage: Due to not being listed domestically, this drug is not included in the Chinese Basic Medical Insurance Drug Catalog.

2. International Approval Status

(1) FDA approval: Accelerated approval for the treatment of IgA nephropathy proteinuria in February 2023, and full approval for delaying renal function decline in May 2024.

(2) Product information: The common name is Sparsentan, and the product name is Filspari.

3. Precautions for obtaining

(1) Purchase channel: Currently, generic drugs can be obtained through regions such as Laos, with a specification of 400mg x 30 tablets and a price of approximately $807.

(2) Risk Warning: Cross border drug purchases require verification of drug qualifications, vigilance against counterfeit drug risks, and compliance with relevant customs regulations.